Ischemic Stroke Clinical Trial
Official title:
The Effects of Posture on Cerebral Blood Flow Velocity During the Acute Phase of Stroke
NCT number | NCT04972812 |
Other study ID # | STH21782 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2021 |
Est. completion date | August 31, 2022 |
Verified date | September 2022 |
Source | Sheffield Hallam University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
After stroke, blood vessels in the brain can become damaged, and the brain's ability to control blood flow can be impaired. The brain therefore may be less able to maintain a healthy level of blood flow during challenges such as changes in posture. Studies have shown that sitting upright early after stroke can cause brain blood flow to reduce. However, no studies have investigated how standing up affects blood flow to the brain. In this study, transcranial Doppler ultrasound will be used to assess how cerebral blood flow velocity changes when acute stroke patients stand up.
Status | Completed |
Enrollment | 32 |
Est. completion date | August 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (age =18 years) patients diagnosed with any subtype of stroke (first or recurrent). - Medically stable, assessed by a stroke physician. - Able to be enrolled between within 7 days of stroke symptom onset. - Able to sit independently. - Able to stand with or without assistance. - Sufficient English language comprehension and cognitive ability to understand the study protocol, give informed consent and follow instructions. Exclusion Criteria: - Autonomic nervous system disorder causing haemodynamic instability e.g. pure autonomic failure, Parkinson's disease, multiple system atrophy and Shy-Drager syndrome - Lower-limb pain when standing. - Restricted range of motion due to spasticity or contracture impairing ability to stand. - Orthopaedic impairment (e.g. bone fracture or ligament rupture) preventing prevent full weight bearing activities. - Resting systolic blood pressure =100 mmHg or =180 mmHg. - Resting diastolic blood pressure =50 mmHg or =120 mmHg. - Significant tachycardia =120 beats per minute at rest. - Significant bradycardia =40 beats per minute at rest. - Peripheral oxygen saturation =85% without use of supplementary oxygen. - Life expectancy <6 months (terminal illness). - Currently participating in another clinical trial that is likely to affect outcome measures (e.g. experimental drug that affects blood pressure or blood vessel tone). - Likely to be discharged from hospital or repatriated within 48 hours of stroke onset. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Hallamshire Hospital | Sheffield | South Yorkshire |
Lead Sponsor | Collaborator |
---|---|
Sheffield Hallam University | Sheffield Teaching Hospitals NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cerebral blood flow velocity (cm/s^1) | Absolute change in bilateral mean middle cerebral artery velocity (cm/s^1) | Day 1 (measured over a 14-minute period) | |
Secondary | Change in cerebral blood flow velocity (%) | Relative change in bilateral mean middle cerebral artery velocity (%) | Day 1 (measured over a 14-minute period) | |
Secondary | Change in blood pressure | Absolute change in mean arterial pressure (mmHg) | Day 1 (measured over a 14-minute period) | |
Secondary | Change in heart rate | Absolute change in heart rate (beats per minute) | Day 1 (measured over a 14-minute period) | |
Secondary | Disability | Modified Rankin Scale (0-5; 0 = no symptoms at all, 5 = severe disability) | Day 1 (at study enrollment) & 3 months post-stroke | |
Secondary | Functional independence | Barthel Index (0-100; <20 = totally dependent, 80-100 = independent) | Day 1 (at study enrollment) & 3 months post-stroke | |
Secondary | Adverse events | Secondary stroke.
Falls. Cardiovascular events. Death. |
3 months post-stroke |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |